News | 30 November 2012
The new guidance includes sales of $10.3bn-$10.7bn on its generic medicines next year, $7.6bn-$8bn on branded generics and $3.7bn-$3.9bn on Copaxone, its patented multiple sclerosis treatment. Mr Levin steered investors away from fresh large-scale ...
Click on the link to read the full article at Financial Times
(This link will open in a new window)